Geron announced that its board has appointed John Scarlett as its Chief Executive Officer and to its board of directors.

Scarlett brings over 25 years of executive leadership experience in the pharmaceutical and biotechnology industry to Geron. Most recently, he served as President and Chief Executive Officer of Proteolix.

David Greenwood, who has served as interim CEO, President and CFO of Geron since February 2011, will remain in his role as President and CFO during a transition period to continue through the end of this year, reporting to Scarlett.

In connection with the transition, Greenwood has resigned from the company's board of directors.